🔴 Exclusive webinar: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Celyad SA (CYAD)

Brussels
Currency in EUR
0.71
+0.04(+6.45%)
Real-time Data
CYAD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
Fair Value
Day's Range
0.680.71
52 wk Range
0.211.22
Prev. Close
0.67
Open
0.68
Day's Range
0.68-0.71
52 wk Range
0.21-1.22
Volume
21,607
Average Volume (3m)
60,663
1-Year Change
13.56%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
CYAD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Celyad SA Company Profile

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Compare CYAD to Peers and Sector

Metrics to compare
CYAD
Peers
Sector
Relationship
P/E Ratio
−3.6x−1.8x−0.6x
PEG Ratio
−0.04−0.010.00
Price/Book
8.5x1.4x2.6x
Price / LTM Sales
385.5x3.9x3.2x
Upside (Analyst Target)
-183.8%43.4%
Fair Value Upside
Unlock14.0%6.4%Unlock

People Also Watch

391.40
PANW
+1.14%
0.237
ALCOX
-1.25%
0.2890
OXUR
+2.30%
0.1188
ALGAU
0.00%
0.0639
ALAGO
0.00%

FAQ

What Is the Celyad (CYAD) Stock Price Today?

The Celyad stock price today is 0.71

What Stock Exchange Does Celyad Trade On?

Celyad is listed and trades on the Brussels stock exchange.

What Is the Stock Symbol for Celyad?

The stock symbol for Celyad is "CYAD."

What Is the Celyad Market Cap?

As of today, Celyad market cap is 27.63M.

What is Celyad Earnings Per Share?

The Celyad EPS is -0.221.

What Is the Next Celyad Earnings Date?

Celyad will release its next earnings report on Nov 10, 2024.

From a Technical Analysis Perspective, Is CYAD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.